NCT Number: NCT00191438
Phase III Study of Gemcitabine Plus a Cytotoxic Agent Versus Two Cytotoxic Agents
This is a phase III randomized study which compares two different regimens of chemotherapy. The purpose of the study is to determine which of the two regimens will make the tumor smaller or disappear, and for how long. In addition the disease-related symptoms will be evaluated. The safety of the drugs will be determined based upon evaluation of the side effects
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Phase 3
Primary location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint-Herblain, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Locally advanced and/or metastatic breast cancer.
- Measurable disease
- Previously treated with anthracycline
Exclusion criteria
- Patients with inflammatory breast disease
Treatment and study plan
Capecitabine
Drugdocetaxel
DrugPrimary outcomes
-
Progression free survival. The final analysis will occur when 250 patients have progressed or died.
Secondary outcomes
-
Overall toxicity
-
Quality of Life
-
Overall Survival
-
Overall Response Rate
-
Time to Treatment Failure
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Registry information
Official study title
Phase III Study of Docetaxel in Combination With Gemcitabine Versus Docetaxel in Combination With Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer
Important dates
- Study start
- 2002
- Study completion
- 2007
- First posted
- Sep 19, 2005
- Registry last updated
- May 28, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
BRCA Mutations in Latinas
NCT01251900
Breast Diseases, Breast Neoplasms
Lubbock, Texas, United States
View Trial DetailsLifestyle, Exercise, and Nutrition Study Early After Diagnosis
NCT03314688
Breast Diseases, Breast Neoplasms
New Haven, Connecticut, United States
View Trial DetailsA Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
NCT04572295
Acrocephalosyndactylia, Bone Diseases
Nagoya, Aichi-ken, Japan
View Trial DetailsA Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
NCT07096024
Breast Diseases, Breast Neoplasms
New York, United States
View Trial Details